Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.
Carcinoma, Non-Small-Cell Lung
DRUG: XL647
Determine the best confirmed response rate, Inclusion until disease progression
Safety and tolerability of XL647 administered daily, First treatment until 30 day post last treatment|Progression-free survival, duration of response, and overall survival, Incusion until disease progression|Further characterize the pharmacokinetic (PK) parameters, Every 8 weeks after Day 57 until disease progression
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.